CSL Limited (OTCMKTS:CSLLY – Get Free Report) was the target of a significant increase in short interest in the month of July. As of July 31st, there was short interest totalling 3,700 shares, an increase of 208.3% from the July 15th total of 1,200 shares. Based on an average trading volume of 37,100 shares, the days-to-cover ratio is currently 0.1 days.
Analyst Upgrades and Downgrades
Separately, Macquarie raised CSL to a “strong-buy” rating in a report on Tuesday.
CSL Price Performance
CSL Company Profile
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
See Also
- Five stocks we like better than CSL
- Why Are These Companies Considered Blue Chips?
- Brinker International’s Price Dip is an Appetizing Entry Point
- Dividend Payout Ratio Calculator
- 3 Stocks That Could Beat the September Blues
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.